Pipeline


Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.

Clinical Pipeline

Bluebird Bio

Lenti-D

Indication: Cerebral ALD

Phase II / III


LentiGlobin BB305

Indication: Beta Thalassemia

Phase III


LentiGlobin BB305

Indication: Sickle Cell Disease

Phase I / II


CelgeneBluebird Bio

bb2121 BCMA

Indication: Multiple Myeloma

Breakthrough Designation


Oxford BioMedica

OXB-201

Indication: AMD

Phase I Completed

OXB-202

Indication: Corneal Graft

Phase I / II


ViaCyte

PEC-Encap VC-01

Indication: T1 and Insulin-requiring T2 Diabetes

Phase I / II

PEC-Direct VC-02

Indication: High-risk T1 Diabetes

Phase I / II


Veana Therapeutics

Oral Vimo-001

Indication: Solid Tumors

Phase I



Pre-Clinical Pipeline

Renova Therapeutics

RT-200

Indication: Type II Diabetes

Advanced Preclinical


RT-300

Indication: Congestive Heart Failure

Preclinical


RT-400

Indication: Acute decompensated heart failure

Preclinical


Mirata BioPharma

MRT-101 – Grb-Fc-IT4

Indication: Breast, Lung, Melanoma Cancers

Preclinical


MRT-201 – Grb-Fc-4D5

Indication: Breast, GEJ Ca Cancers

Preclinical


MRT-301 – Grb-Fc-HMEL

Indication: Melanoma, Breast Cancers

Preclinical


H2 Biologics

GrB-Fc-SD1

Indication: Mesotheliomas & Pancreatic Cancers

Preclinical


Available for Licensing

Dengue Tetra Vaccine

Indication: Dengue Fever

IND Package

Chik Vaccine

Indication: Chikungunya

Preclinical



Early Stage Pipeline

Abologix

JamC mAb

Indication: B Cell Lymphomas

Animal in vivo POC


Olf mAb

Indication: Metastatic breast cancer

Animal in vivo POC


SrpX2 mAb

Indication: TBD

Animal in vivo POC


Available for Licensing

Zika Vaccine

Indication: Zika

Candidate Selection


SmartKnife

Applications: Chronic Total Occlusions (CTOs), Endometriosis, Brain tumors

Prototype development


CRFR1 antagonist

Indication: AD and related tauopathies

Candidate Selection


Grp78 mAb

Indication: Ovarian cancer

Candidate Selection


Fillagrin-RMR

Indication: Severe Icthyosis Vulgaris

Animal in vivo POC


Fc domains

Platform: Various applications

Research


Stem Cell Safety Switch

Indication: Stem Cell Therapy in CNS (PD…)

Preclinical


E. canis Vaccine

Indication: Ehrlichiosis Canis

Research